Abstract 5138
Background
Reliable biomarkers to predict response to immunotherapy is crucial for patients’ counseling and decision making. This study was aimed to identify the role of CT radiomic features in predicting response to immunotherapy in patients with recurrent or metastatic urothelial carcinoma.
Methods
A total of 62 patients with their 224 lesions who underwent PD-1 and PD-L1 immunotherapy between March 2015 and November 2017 were retrospectively analyzed. The patients were temporally divided into training sets (n = 41; 155 lesions) and independent test set (n = 21; 69 lesions). For radiomics feature extraction, two radiologists independently segmented the region of interest at baseline CT on portal venous phase. A radiomics signature (RAD score) was built by using the least absolute shrinkage and selection operator (LASSO) method. The diagnostic performance of RAD score for prediction of response to immunotherapy was evaluated by C statistics.
Results
The overall response rate of immunotherapy was 36.6% in the training set and 28.8% in the test set. RAD score revealed the C statistics of 0.83 (95% CI, 0.68–0.93) in the training set and a corresponding C statistics of 0.71 (95% CI, 0.48–0.89) in the test set.
Conclusions
This study suggests that radiomic features extracted from metastatic masses at baseline CT are predictive of response to immunotherapy in patients with recurrent or metastatic urothelial carcinoma.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
5105 - Fresh blood Immune cell monitoring in patients treated with nivolumab in the GETUG-AFU26 NIVOREN study: association with toxicity and treatment outcome
Presenter: Aude DESNOYER
Session: Poster Display session 3
Resources:
Abstract
1877 - Advanced clear-cell renal cell carcinoma (accRCC): association of microRNAs (miRNAs) with molecular subtypes, mRNA targets and outcome.
Presenter: Annelies Verbiest
Session: Poster Display session 3
Resources:
Abstract
5543 - Prior tyrosine kinase inhibitors (TKI) and antibiotics (ATB) use are associated with distinct gut microbiota ‘guilds’ in renal cell carcinoma (RCC) patients
Presenter: Valerio Iebba
Session: Poster Display session 3
Resources:
Abstract
2689 - mTOR mutations are not associated with shorter PFS and OS in patients treated with mTOR inhibitors
Presenter: Cristina Suarez Rodriguez
Session: Poster Display session 3
Resources:
Abstract
3069 - Efficacy of immune checkpoint inhibitors (ICI) and genomic alterations by body mass index (BMI) in Advanced Renal Cell Carcinoma (RCC)
Presenter: Aly-Khan Lalani
Session: Poster Display session 3
Resources:
Abstract
5089 - Finding the Right Biomarker for Renal Cell Carcinoma (RCC): Nivolumab treatment induces the expression of specific peripheral lymphocyte microRNAs in patients with durable and complete response.
Presenter: Lorena Incorvaia
Session: Poster Display session 3
Resources:
Abstract
2594 - Algorithms derived from quantitative pathology can be a gatekeeper in patient selection for clinical trials in localised clear cell renal cell carcinoma (ccRCC)
Presenter: In Hwa Um
Session: Poster Display session 3
Resources:
Abstract
2566 - High baseline blood volume is an independent favorable prognostic factor for overall and progression-free survival in patients with metastatic renal cell carcinoma
Presenter: Aska Drljevic-nielsen
Session: Poster Display session 3
Resources:
Abstract
2675 - Impact of estimand selection on adjuvant treatment outcomes in renal cell carcinoma (RCC)
Presenter: Daniel George
Session: Poster Display session 3
Resources:
Abstract
1541 - TERT gene fusions characterize a subset of metastatic Leydig cell tumors
Presenter: Bozo Kruslin
Session: Poster Display session 3
Resources:
Abstract